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Abstract
Gene expression data can provide a very rich source of information for elucidating the biological function on the pathway
level if the experimental design considers the needs of the statistical analysis methods. The purpose of this paper is to
provide a comparative analysis of statistical methods for detecting the differentially expression of pathways (DEP). In
contrast to many other studies conducted so far, we use three novel simulation types, producing a more realistic correlation
structure than previous simulation methods. This includes also the generation of surrogate data from two large-scale
microarray experiments from prostate cancer and ALL. As a result from our comprehensive analysis of 41,004 parameter
configurations, we find that each method should only be applied if certain conditions of the data from a pathway are met.
Further, we provide method-specific estimates for the optimal sample size for microarray experiments aiming to identify
DEP in order to avoid an underpowered design. Our study highlights the sensitivity of the studied methods on the
parameters of the system.
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Introduction
The functional analysis of high-throughput data is a challenging
but promising direction in the post-genomics era. It is challenging
because genome-wide data are high-dimensional and noisy, but
promising due to its potential to reveal knowledge about the
systemic working mechanisms of biological information processing
within cells, which we are currently lacking [1–4].
In the context of expression data the interest shifted in recent
years from approaches focusing on the analysis of individual genes,
detecting their differentially expression [5–7], toward the analysis
of gene sets in order to identify differentially expressed sets of genes
[8–11]. The rational behind this is that genes and their products
do not work in isolation but interact with each other in a concerted
manner in order for a phenotype to emerge [12]. Many univariate,
multivariate and nonparametric statistical methods have been
either newly developed or existing methodological techniques have
been adapted for this problem [13–16]. One important property
that allows to distinguish different types of such hypotheses tests
was discussed in [17]. There, tests have been distinguished based
on the data used for the comparison. A hypothesis test comparing
a gene set to all other gene sets available is called competitive,
whereas a test comparing the same gene set for two different
phenotypes is called self-contained.
The name ‘gene set’ associated with the above methods implies
that the choice for defining gene sets by populating them with
specific genes is not constraint. However, in the present study, we
are considering only gene sets that have been defined by using
biological information regarding their association with specific
pathways extracted, e.g., from the gene ontology database [18] or
KEGG [19]. For this reason we refer to them in the following as
pathway-based methods [20] to indicate this explicitly.
The major goal of this paper is to compare two self-contained
(sum of t-square and Hotelling’s T2 [21,22]) and one competitive test
(GSEA [23]) with each other, for a variety of simulated and
biological expression data, in order to gain insights into the
dependence of the power of these methods on the correlation
structure among genes. The reason for selecting these tests is their
complementary nature, representing univariate (sum of t-square),
multivariate (Hotelling’s T2) as well as competitive and self-
contained tests. In [24] it has been shown that there are currently
only about three different null hypotheses effectively tested among
all self-contained tests, which include the null hypothesis of the sum
of t-square test and Hotelling’s T2. Because GSEA is a competitive
test, its null hypothesis is conceptually different to the above ones
making the three selected methods complementary to each other
with respect to the tested null hypotheses. The reason for choosing
GSEA over other competitive methods, which are based on
methodological extensions [25,26], is the popularity of this method
especially among biologists [27], and the vast number of studies it
has been already used for.
In contrast to the many studies that have been conducted so far
investigating the power of methods for identifying differentially
expressed pathways, we are focusing on the correlation structure in
gene expression data. Other studies conducted in this context
either did not consider the correlation among genes [25,28],
assumed a constant [13,29], a random [30], an autoregressive [31]
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[14,32,33] or studied real microarray data only [34–36], which do
not allow to study different configurations by adjusting model
parameters. The main problem with the above simulation studies
is that they do not provide a realistic correlation structure among
genes. The reason for this is that the made assumptions do not lead
to a gene network-like correlation structure as observed for gene
expression data. Technically, this means that the inverse of the
covariance matrix does not reflect the independence relations that
can be found in such network structures, as we will discuss in detail
in section ‘Simulation of network-like correlation structure’.
However, due to the fact that we are only considering gene sets
that correspond to biological pathways, the strength of the
correlation and its structure are important parameters that need
to be controlled properly in order to make the transition from gene
sets to pathways. In order to overcome this severe limitation, two
algorithms have been developed, in a different context, for
generating a covariance matrix for a multivariate normal
distribution whose inverse is consistent with the independence
relations of a network [37,38]. In order to generate such a
covariance matrix, both methods need a network as an input for
their algorithm. For our simulation study, we employ both
algorithms for generating simulated expression data with a gene
network-like correlation structure by using a protein interaction
network and a transcriptional regulatory network from yeast as
input network. This provides a biologically realistic constraint on
the resulting correlation structure. In the following we call these
simulation types III and IV. Here by ‘biologically realistic’ we mean
that an experimentally determined protein interaction network
and a transcriptional regulatory network are more realistic than
artificially generated network structures using a statistical method.
In order to conduct a comprehensive analysis of important system
parameters, we include in our study also the influence of the
sample size, detection call, i.e., the percentage of genes that is
differentially expressed within a pathway, and the pathway size on
the identification of differentially expressed pathways.
In addition to simulated expression data, we use also two large-
scale cancer data sets from DNA microarray experiments [39,40].
By applying a bootstrap approach [41,42], we use these data sets
to generate surrogate data of smaller sample sizes. This allows us
to study the robustness of the statistical methods over a wide range
of realistic sample sizes without the need for making assumptions
about the underlying pathology of the pathways in order to
declare, e.g., pathways as true positives. Further, we compare the
correlation structure of simulated and biological pathways as
defined via the gene ontology database [18].
Methods
Pathway-based method
GSEA. This method was introduced by [11,23] in order to
identify the differential expression of predefined gene sets. GSEA
is considered a competitive test [17] because it compares a test set
to a background data set. Let W be the set of genes to be tested
and Wc its complement in a way that the union of both sets gives
all genes, i.e., V~W|Wc. Briefly, GSEA consists of the
following steps, applied to each pathway:
(1) Estimation of gene-wise test statistics.
(2) Rank ordering of the test statistics.
(3) Calculation of an enrichment score (ES) for a pathway.
(4) Permutation of the gene-labels to estimate the significance of
the enrichment score (p-value) for the pathway.
The hypotheses tested by GSEA are:
H0 : ES~0 - vanishing test score
H1 : ES=0 - non-vanishing test score
Hotelling’s T2. The Hotelling T2 test is a self-contained test
that is a multivariate generalization of the univariate t-test. Its null
and alternative hypothesis can be formulated as:
H0 : mT~mC - equality of the p-dimensional population
mean vectors
H1 : mT=mC - difference of the p-dimensional popula-
tion mean vectors
Suppose we have two groups with nC samples from the control
group and nT samples for the treatment group, each consisting of
p genes. Let the expression level of the ith sample of the control
group and treatment group be given by XC
i ~(XC
i1,XC
i2,...XC
ip)
t
and XT
i ~(XT
i1,XT
i2,...XT
ip)
t, respectively. The pooled covariance
matrix S is then defined by
S~
(nT{1)STz(nC{1)SC
(nTznC{2)
ð1Þ
where SC and ST are the covariance matrices for the control and
treatment group. Hotelling’s T2 is defined as
T2~
nT|nC
nTznC
(mT{mC)S
{1(mT{mC)
t: ð2Þ
The inverse of the covariance matrix is estimated via the shrinkage
estimator [43–46]. The statistical significance of the test statistic
T2 is estimated from sample-label permuted data.
Sum of t-square. The sum of t-square test is an univariate test
based on t-scores, ftig, obtained for each of the p genes
individually for a given set [22]. The test statistic for each
pathway is given by
X
t,2
~
1
p
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
X p
i
t2
i
s
: ð3Þ
Its null and alternative hypothesis can be formulated as:
H0 :
P
t,2 ~0 - vanishing test score
H1 :
P
t,2 =0 - non-vanishing test score
Again, the significance of
P
t,2 is assessed from sample-label
permuted data.
Simulation algorithms
In order to assess the performance of the statistical methods we
use three principally different algorithms to simulate expression
data.
Simulation of uncorrelated data. For this method we, first,
define different non-overlapping pathways of varying sizes
including a total of p genes. Then we draw iid (Independent and
identically distributed) samples from a standard normal distribu-
tion, i.e., XG
ij *N(0,1), for each gene i[f1,...,pg and sample
j[f1,...,ng, for the control (G~c) and treatment (G~t) group. In
order to make a difference between the control and treatment
group we add a constant factor of one to a certain percent of genes
of all pathways for the treatment group.
Power Analysis for Pathways
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X with p rows and 2n columns with a sample size of n for the
control and treatment group, i.e., Xij with j[f1,...,ng corre-
sponds to the control and j[fnz1,...,2ng to the treatment
group. Each component of X is independently sampled from a
standard normal distribution, i.e., Xij*N(0,1). Then we generate
a 2n-dimensional random vector a whose components are also iid
drawn from the standard normal distribution. Define
Yij~
ﬃﬃﬃ
r
p
ajz
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1{r
p
Xij ð4Þ
where i[f1,...,pg and j[f1,...,2ng, so that the average
correlation between the genes (rows of Y)i sr [29]. To model
differential expressed pathways we add a constant factor of one to
a certain percent of genes for the treatment group.
Simulation of a network-like correlation structure. For
random variables that are from a p-dimensional multivariate
normal distribution, i.e., Xp*N(m,S), a simple relation between
the components of the inverse covariance matrix V~S{1 (also
called precision or concentration matrix) and the conditional
partial correlation holds [47]
rijDV\fijg~{
vij
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ viivjj
p : ð5Þ
Here rijDV\fijg is the partial correlation coefficient between gene i
and j conditioned on all remaining genes and vij are the
components of V. That means if rijDV\fijg~0 then gene i and j are
independent from each other,
Xi\XjDfall remaining genesg, ð6Þ
if and only if vij~0. A multivariate normal distribution that is
Markov with respect to an undirected network G is called a Gaussian
graphical model. This means that all conditional independence
relations that can be found in S{1 hold also in G [47]. Hence,
such a S{1 can be considered as consistent with all conditional
independence relations in G.
We use the following two algorithms to obtain a covariance
matrix for a given network structure G.
(1) The algorithm of [38] is based on successive orthogonal
projections constraint by the network structure G, resulting in
a consistent covariance matrix S.
(2) The algorithm of [37,48] is based on proportional iterative
fitting [47] to enforce an average correlation in the data
resulting in a covariance matrix S consistent with the
conditional independence relations in G.
As input network G for these algorithms we use two yeast
networks. The first is a protein-protein interaction network
provided by the Biogrid database [49] and the second is a
transcriptional regulatory network [50]. From both networks, we
extract the giant connected component. The reason for selecting
these networks is that a protein and a transcriptional regulatory
network represent observed interaction structures among genes and
gene product and, hence, provide a more realistic structure than
artificially generated networks, e.g., by using the preferential
attachment model to generate scale-free networks [51]. Once a
covariance matrix S from one of the above algorithms is obtained,
we use S to generate iid samples from a multivariate normal
distribution, i.e., X*N(m,S). In order to simulate the differen-
tially expression of pathways, we use a p-dimensional mean vector
of zero, m~0p, for the control group, and a mean vector m
consisting of DC genes with an expression of 1 and (1{DC) genes
with an expression of 0 for the treatment group. For both groups,
we use the same covariance matrix.
We would like to note that due to the properties of the Gaussian
graphical model, as discussed above, this model has been used to
infer gene regulatory networks from expression data [46,52–54].
This indicates that the relation between the components of the
inverse of the covariance matrix and the independence relations
found in a network structure are generally considered to be
biologically connected with each other for expression data. Hence,
this provides a justification to consider the correlation structure
generated from a Gaussian graphical model as biologically
plausible.
Simulation types
For our analysis we are using four different simulation types
(ST) based on the algorithms described above. Because GSEA is a
competitive test [17] it requires a background data set against which a
pathway is compared. For ST I we simulate such a background
data set explicitly. This background data consists of 10000 genes
with expression values sampled from a normal distribution N(0,1),
for both conditions, and a global correlation structure is imposed
by Eqn. 4. For ST II–IV we use, instead, the remaining data
excluding the pathway under investigation, as background data.
Simulation type I. For this type of simulation we generate
simulated expressed data for all p~10000 genes simultaneously, as
described in methods section ‘Simulation of uncorrelated data’
and ‘Simulation of correlated data’, for which we define non-
overlapping pathways of sizes ranging from 5 to 195 (step size 10),
P~f5,15,...,195g. For each of these DPD~20 different pathway
sizes we generate 5 pathways, resulting in a total of 100 different
non-overlapping pathways that contain in total p~10000 genes.
Parameters studied: We study the influence of the sample size
(n[N~f5,10,15,...,45g, DND~9), detection call
(DC[DC~f0%,10%,30%,60%g, D jj ~4) and of the correlation
(r[R~f0:0,0:2,0:4,0:6g, DRD~4). Here, the detection call (DC)
[24] refers to the percent of differentially expressed genes in a
pathway and r refers to the correlation between all genes in the
overall set. This gives 2880(~DPD:DND:DDD:DRD) different parameter
configurations. For GSEA, we generate a background data set
without expression difference between the treatment and control group,
i.e., Xt
ij,Xc
ij*N(0,1).
Simulation type II. Here we generate simulated data
separately for each pathway, as described in methods section
‘Simulation of correlated data’. In contrast to ST I, ST II
generates a correlation among the genes within a pathway. We use
an overall set of p~10000 genes to define non-overlapping
pathways, as for ST I. Parameters studied: We study the influence
of the sample size (n[N~f5,10,15,...,45g, DND~9), detection
call (DC[DC~f0%,10%,30%,60%g, D jj ~4) and of the correla-
tion (r[R~f0:2,0:4,0:6g, DRD~3). Here, r refers to the correla-
tion for the genes within a pathway, whereas the average
correlation among all genes is about zero. This gives
2160(~DPD:DND:DDD:DRD) parameter configurations.
Simulation type III and IV. For this ST we generate
simulated expressed data by sampling from a p-dimensional
Gaussian graphical model. In order to obtain a more realistic
correlation structure we use two different algorithms, as described
in methods section ‘Simulation of network-like correlation
structure’ in combination with a protein interaction network and
a transcriptional regulatory network. We used the gene ontology
database [18] to map the proteins to their corresponding biological
process for level 4. From this information we selected 76 different
Power Analysis for Pathways
PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e37510but overlapping pathways that consist in total of p~1588 genes for
algorithm (1) and 41 pathways for 612 genes for algorithm (2). For
the transcriptional regulatory network we select 200 different but
overlapping pathways that consist in total of p~1199 gene for
algorithm (1) and (2). Parameters studied for both algorithms: We
study the influence of the sample size (n[N~f5,10,15,...,45g,
DND~9) and the detection call (DC[DC~f0%,10%,30%,60%g,
DDCD~4). The overall average correlation between all genes is
approximately zero. In addition, for algorithm (2) we study also
different values of the correlation, (r[R~f0:2,0:4,0:6g, DRD~3).
This gives 2736(~N:D:76) (ST III) and 4428(~N:D:R:41) (ST
IV) different parameter configurations for the protein interaction
network and 7200(~N:D:200) (ST III) and
21600(~N:D:R:200) (ST IV) different parameter configurations
for the transcription regulatory network.
We would like to note that in the results section, the estimates
for the false positive rate (FPR) have been obtained by setting
DC~0%, which corresponds to the case of no differentially
expressed pathways [15,24,25].
Surrogate data: ALL and prostate cancer
To assess the power of the three pathway-based methods for
microarray data we use two different large-scale data sets based on
Affymetrix chips. The first is a prostate cancer data set consisting
of 50 control samples and 52 tumor samples [40]. The second data
set is from B-cells derived from Acute lymphoblastic leukemia
(ALL) [39]. From the entire data set we select 37 samples from the
BCR/ABL group and 37 from the NEG group. For the
preprocessing and normalization of these data sets we followed
[39,40]. After the normalization, we map the genes to the category
biological process of level four in the gene ontology database [18] in
order to obtain information about their association to biological
pathways. For prostate cancer we obtain 213 different pathways
and for ALL 533.
Our analysis of these data consists of two steps. In the first step,
we generate a reference list by testing the significance of pathways
for the total number of samples s (prostate: s=102, ALL: s=74).
For the following analysis we use the results from this analysis as
reference, because we consider the significant pathways as true
positives and the nonsignificant pathways as true negatives. In the
second step, we construct b(si) bootstrap data sets for various
sample sizes, s1ws2w   wsk{1wsk, each data set drawn from
the total of s available samples. For each bootstrap data set, each
method is applied and a p-value obtained for each pathway. From
this, a result is assessed as true positive, true negative, false positive
or false negative with respect to the reference list obtained for
sample size s (step one). Due to the fact that our reference list may
contain false declarations, our results assess the statistical
robustness of the methods providing estimates for, e.g., their
power, rather than their true value. Further, because we generate
bootstrap data sets for each sample size si, we consider these as
surrogate data for newly generated data from independent
experiments, which are not available.
Results
For the following simulations, we use a significance level of
a~0:05.
Simulation type I and II
In Fig. 1 A-C we show the power for GSEA (red curves),
Hotelling’s T2 (green curves) and sum of t-square (blue curves) for
simulation type I and II and different parameter settings. Here by
the power we mean the probability that the statistical hypothesis
test is rejected when the null hypothesis is truly false [55].
Practically, we estimate this probability by the population mean
over repeated simulations [24]. The different color shadings code
for different DC values; DC=10% (light color), 30% (medium
color), 60% (dark color). In these figures, a ‘dot’ corresponds to a
mean value, and the error bars refer to its standard deviation
obtained from 50 bootstrap samples. Each figure is indexed by the
strength of the mean correlation.
For ST I (Fig. 1 A) the correlation has a much stronger influence
on the power of sum of t-square and GSEA than on Hotelling’s T2,
although Hotelling’s T2 has generally a lower power. Also, the
influence of the detection call is for the sum of t-square and GSEA
strongest resulting in a considerable loss in power for DCv30%.
Hotelling’s T2 appears to be relative insensitive against different
values of DC. For high correlations and DC~10% the sum of t-
square test has by far the worst power. For ST II (Fig. 1 C) GSEA
performs significantly worse for all values of DC, compared to
simulation type I, showing an almost complete break down. The
power of sum of t-square and Hotelling’s T2 are comparable to the
results for ST I. Regarding the number of significant pathways
detected by the three methods, one can see that the sum of t-square
test declares consistently more pathways as significant than any
other method, for all conditions, except for very small sample sizes
(ƒ10) for ST I. In this case GSEA declares more pathways as
significant. In general, the lower the DC value the lower the
number of pathways declared as significant, whereas lower values
having a stronger influence. Further, it is interesting to note that
for r~0:0 (Fig. 1 B) the sum of t-square and Hotelling’s T2 are
different from each other despite that fact that in this case both
tests should provide similar result, because the pooled covariance
matrix S (see Eqn. 1) becomes diagonal. This indicates a poor
behavior of the shrinkage estimator.
For ST II GSEA declares considerably less pathways as
significant compared to the other methods, for all conditions.
Regarding the false positive rate (FPR), GSEA and sum of t-square
show a good control of the FPR at a significance level of a~0:05.
This is in contrast to Hotelling’s T2 which has even for large
sample sizes a FPR larger than 0:20. In order to find the cause for
this behavior we split the pathways into two categories. In the first
category we put all pathways having less than 35 genes, in the
second category we place all larger pathways (results not shown).
From this analysis we find that also Hotelling’s T2 controls the
FPR, but only for pathway sizes less than 35. The reason for this
behavior is related to the estimation of the inverse of the
covariance matrix, S{1, on which Hotelling’s T2 is based. For
smaller pathways, their number of genes, p, is closer to the number
of samples, nC and nT, and, hence, the estimates for S{1 are more
accurate than for larger pathways. Hence, for larger pathways one
would need to improve the shrinkage estimator. Figure 1 B shows
the result for uncorrelated data (r~0:0). In this case ST I and II
coincide with each other. In general, for the uncorrelated case the
power is slightly higher for all methods and also the number of
pathways declared significant increases.
Simulation type III and IV
Fig. 2 (A and B) shows the results for simulation type III and IV.
Here the sum of t-square and Hotelling’s T2 perform much better
than GSEA. Interestingly, for ST IV and high correlations (r~0:6)
and small sample sizes (ƒ25) the power of Hotelling’s T2 is even
slightly higher than for the sum of t-square test and, more
importantly, it is more robust with respect to DC values less than
60%. For the number of significant pathways we find again that
GSEA declares less pathways as significant. Hotelling’s T2 does
not control well the false positive rate for small sample sizes (ƒ20)
Power Analysis for Pathways
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correlations. For the sum of t-square the FPR is in general
controlled, except for ST IV and r~0:6. It is of interest to note
that GSEA is the only method that controls the FPR for all
conditions well.
The significant reduction of the power for GSEA for simulation
type I compared to simulation type II to IV can be explained by
the background data that have been generated for simulation type
I, but not for the other simulation types. Due to the fact that
GSEA is a competitive hypothesis test which estimates a test
statistics w.r.t the background, the background data have a
prominent influence on the power of GSEA whereas a large
background dataset without expression changes in the conditions
increases the sensitivity of this test.
In Fig. 3, we show similar results as in Fig. 2, however, for the
transcriptional regulatory network of yeast [50] instead of the
protein network, to generate simulated data. Overall, these results
have a large resemblance to the results in Fig. 2. This demonstrates
that structural properties of both networks on the pathway level
are sufficiently similar to each other to result in similar results for
the pathway methods. This corresponds, e.g., to the known
similarity of the scale-free degree distribution of these networks
[56].
Surrogate data: ALL and prostate cancer
The results for prostate cancer (left) and ALL (right) are shown
in Fig. 4. We want to re-emphasize that we used the pathways
declared as significant for the total number of samples (prostate:
s=102, ALL: s=74) as a reference list. Hence, the power is
related to these pathways and not to the truely expressed pathways.
Similarly, the interpretation for the FPR and the number of
significant pathways. On the first sight, all methods seem to
perform similarly, although, GSEA has for high sample sizes the
lowest power. However, Hotelling’s T2 and sum of t-square declare
for all studied sample sizes many more pathways as significant
than GSEA. Similar to the simulation studies, GSEA controls the
FPR well whereas the other two methods assume larger values.
An interesting observation of the power is its rapid decay for an
even slightly reduced sample size. More precisely, for prostate
cancer the total sample size is s~102 for which we identified the
set of significant pathways we consider as ‘true positives’.
However, when using only 90 bootstrap samples (45 samples per
condition) then the power of all three methods is already smaller
than 1, see Fig. 4. Even more severe effects are observed for ALL,
where the total sample size is s~74, and results for 64 bootstrap
samples (32 samples per condition) show a clearly reduced power.
This lack of robustness for the initial sample sizes (45 for prostate
cancer and 32 for ALL) suggests that the available total sample sizes
are too small for the employed test statistics, because otherwise we
would observe a stable plateau as in Fig. 1, 2 and 3, where a slight
reduction of the sample size does not influence the power at all.
Hence, from this decay, one can conclude that the total number of
samples (prostate: s=102, ALL: s=74) of both cancer data sets
(ALL and prostate cancer) is not sufficiently large for the point
estimator of the power to converge. This hints to a refinement of
the experimental design of studies aiming to detect the DEP to
avoid a study that is underpowered.
In order to quantify this observation, we performed a linear
regression analysis. For this analysis we use the size of the
microarray experiments as predictor variable and the initial step
size of the power curves (Fig. 4) as outcome variable, measured by
its distance to convergence, as found from the comparison with our
simulation results in Fig. 2 and 3. That means from Fig. 2 and 3
we obtain the minimal sample sizes for which the power reaches
‘1’, and the initial step size of the power corresponds to the power
for 45 (prostate cancer) and 32 (ALL) samples from Fig. 4. We are
only using the results from ST III and IV for this comparison,
because they resemble more closely the correlation structure of
real microarray data. We conduct a separate analysis to predict the
optimal sample size for each method, see Fig. 5. Here optimal refers
to the minimal sample size for a method to become invariant
against the removal of a small number of samples.
For the regression, we obtain F-statistics (18:83, 7:93 and 25:6)
for the three linear regressions, in the order of the figures in 5,
which are all significant with p-values of 0:0006, 0:0145 and
0:0071. As a result of this analysis, we predict a sample size of 59
for Hotelling’s T2 and 57 for the sum of t-square test (red crosses in
Fig. 5). Due to the fact that for GSEA, its power does not converge
in our simulation study for ST III and IV, we cannot make a
prediction for this method. If we use the results form ST I instead,
we obtain an estimated sample size of 83 for GSEA. We would like
to emphasize that we consider these estimates as optimistic and,
hence, as lower bounds for optimal sample sizes since the
simulations constitute only approximations of real data.
A central topic of this paper is the investigation of the influence
of the correlation strength and its structure on the identification of
differentially expressed pathways. In the introduction we presented
arguments supporting the need for such an analysis. Now we add
quantitative evidence, directly extracted from the used expression
data from prostate cancer and ALL. As discussed in the methods
section ‘Surrogate data: ALL and prostate cancer’, both micro-
array data sets were normalized. Estimating the average correla-
tion among all genes from the normalized data results in 0:0618
and 0:0138 for ALL and prostate cancer, which are quite small
correlation values. However, if we estimate the average correlation
among all genes within each pathway, we obtain an entirely different
result. In Fig. 6 we show these results by ordering the pathways
according to their average correlation coefficient. The different
number of the pathways results from the fact the we consider 213
pathways for prostate cancer and 533 pathways for ALL, as
explained in section ‘Surrogate data: ALL and prostate cancer’.
Despite the fact that the average correlation among all genes is
0:0618 for ALL (blue) and 0:0138 for prostate cancer (violet),
shown as dashed lines in Fig. 6, one can clearly see that within the
pathways there is a non-neglectable correlation, which spans a
very wide range of different values, as summarized by the two
vertical intervals on the left-hand side (violet: prostate cancer; blue:
ALL). From these results, we can draw the following conclusions.
First, even in normalized expression data there exist quite large
correlations within particular pathways, which exhibit much larger
values than the average correlation between all genes in the data
set. The reason for this is that the purpose of any normalization
method is to reduce reduce correlations due to technical artifacts
and batch effects in the data but not real biological correlations
between genes. These results justify also the selected correlation
values for our simulations, which assume correlations up to 0:6.
Second, there is a wide dynamic range of observed correlation
coefficients that points toward a heterogeneity among the
pathways. That means not all pathways possess the same
characteristics but they can be quite different from each other.
Figure 1. Simulation type I (A, B) and II (C): Power, FPR and number of significant pathways for GSEA (red), sum of t-square (blue)
and Hotelling’s T2 (green). DC=10% (light color), 30% (medium color), 60% (dark color).
doi:10.1371/journal.pone.0037510.g001
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PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e37510Figure 2. Simulation type III (A) and IV (B): Power, FPR and number of significant pathways for GSEA (red), sum of t-square (blue) and
Hotelling’s T2 (green). DC=10% (light color), 30% (medium color), 60% (dark color). Simulated data are from the protein network of yeast [49].
doi:10.1371/journal.pone.0037510.g002
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PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e37510Figure 3. Simulation type III (A) and IV (B) : Power, FPR and number of significant pathways for GSEA (red), sum of t-square (blue) and
Hotelling’s T2 test (green). DC=10% (light color), 30% (medium color), 60% (dark color). Simulated data are from the transcriptional regulatory
network of yeast [50].
doi:10.1371/journal.pone.0037510.g003
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PLoS ONE | www.plosone.org 9 May 2012 | Volume 7 | Issue 5 | e37510For comparison with the simulated data, we include in Fig. 6 the
correlation values for ST I to IV for different parameters. The
vertical intervals on the right-hand side correspond to the
projected correlation range of these four simulation types. Ordered
from left to right: ST I (green: r~f0:0,0:2,0:4,0:6g), ST II
(orange: r~f0:2,0:4,0:6g), ST III (purple: r~f0:0g) and ST IV
(brown: r~f0:2,0:4,0:6g). Here, we represent only the projected
correlation range to simplify the presentation in Fig. 6. However,
we would like to note that for each of these individual results the
ordering of the correlation values assumes a similar shape as
observed for prostate cancer and ALL. From these intervals, two
observations are important to emphasize. First, ST I and II result
in a shorter range for individual simulations, compared to ST III
and IV. Second, the intervals for I and II are non-overlapping.
Overall, we observe that if ST III and IV are employed together,
the whole range of experimentally observed correlations found
within normalized microarray data can be covered without gaps.
Further, in comparison to the correlation structures used in
previous studies, as discussed in the introduction, we find that ST
III and IV provide a more realistic correlation structure compared
to studies using a constant [13,29], random [30], autoregressive
[31], compound symmetry [14,32,33] or no correlations at all
[25,28].
We would like to point out that results about the range of the
correlation values is only one indicator that should be met by
simulated data. In addition, the structure among the genes is
another important characteristics. Due to the fact that the data for
ST III and ST IV are generated in a way that the inverse of the
covariance matrix does reflect the independence relations that can
be found in a protein network, this is another crucial difference to
previous studies equipping our approach with a more realistic
correlation structure.
Finally, we present results about the biological distribution of
DC values in prostate cancer and ALL. Using SAM [57] and a
multiple hypotheses correction [58] we identify differentially
expressed genes in prostate cancer and ALL for FDR~0:05.
From this, we estimate a mean DC value of 18% for prostate
cancer and 4:5% for ALL; see Fig. 7 for the distributions. Further,
we find that only very few pathways have a DC value larger than
30%, namely, 30 out of 213 pathways (corresponding to 14%)i n
prostate cancer and 2 out of 533 pathways (corresponding to 0:3%)
in ALL. This provides evidence that the selected DC values for our
simulations correspond to biologically relevant values.
Discussion
For our power analysis of simulated data, we assumed a
maximum sample size of 50 because this corresponds well to the
number of samples available for the experimental microarray data
we used. Further, most other microarray experiments conducted
provide usually less than 50 samples per condition making our
choice from a biological point of view reasonable. Our results
reveal the following. The sum of t-square test has for almost all
studied cases the highest power if DC§30%, except for ST IV
and r~0:6. However, if DCv30% and rw0:2 Hotelling’s T2 has
a higher power. Due to the fact that this reflects the characteristics
of the microarray data better, Hotelling’s T2 seems to be the
favorable test. The sum of t-square test controls in general the FPR
well, except for ST IV and r~0:6. The control of the FPR of
Hotelling’s T2 depends strongly on the pathway size, and a control
is only working for pathway sizes less than 35. GSEA is for almost
all studied cases underpowered, except for ST I and DC~60%
which is a condition that has not been found in one pathway in
both microarray data sets. In our experience, this problem cannot
be solved by increasing the sample size but is caused by inappropriate
background data, which is out of the control of the experimenter.
On the other hand, GSEA has a good control of the FPR for all
conditions.
Taking all this into account our findings do not suggest to apply
a method unconditionally to all pathways in a given data set, but
to filter them in order to eliminate conditions for which a method is
more likely to cause problems. We suggest to filter the pathways
according to the following easy to check criteria: Hotelling’s T2
should only be applied to pathways with less than 35 genes and a
sample size larger than 30. The sum of t-square test should only be
used for pathways with DCw10% and a sample size of 25 or
larger. GSEA should only be used for pathways with DCw10%
and a sample size larger than 25. We want to emphasize that these
sample sizes are different to the minimal sample sizes discussed in
section ‘Surrogate data: ALL and prostate cancer’, which consider
only the control of the FPR, whereas the optimal sample sizes
avoid in addition that a study is underpowered. It is interesting to
Figure 4. Left column: prostate cancer. Right column: ALL. Power, false positive rate and number of significant pathways for GSEA
(red), sum of t-square (blue) and Hotelling’s T2 (green).
doi:10.1371/journal.pone.0037510.g004
Figure 5. Left: Hotelling’s T2, Middle: sum of t-square, Right: GSEA. The regression line is used to predict the optimal sample size (red cross)
found from the intersection of the regression line with the horizontal dashed line corresponding to a ‘zero distance to convergence’.
doi:10.1371/journal.pone.0037510.g005
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given, however, for the stability of clusters obtained from
clustering algorithms. Despite the methodological differences
among these studies, this correspondence is interesting because it
emphasizes that there is a considerable difference between studies
for detecting the differentially expression of (single) genes and
studies for identifying differentially expressed pathways. For the
former it would be plausible to expect lower sample size
recommendations than for a clustering analysis trying to estimate
the correlation strength among genes. However, due to the fact
that our sample size recommendations for DEP methods coincide
with clustering methods, hints, that DEP analysis methods are not
just the sum of individual gene test statistics. If one perceives this
problem from a biological perspective, this correspondence
becomes more plausible because the clustering of genes is
frequently used to reveal functional relations between genes
corresponding to biological pathways [60–62]. Hence, clustering
algorithms and pathway methods respond to similar molecular
functional units.
The underlying rationale for our power analysis, which provides
statistical estimates of the true positive rates of tests, is to study the
unbiased performance of the methods. In contrast, by conducting
multiple hypotheses tests one would be obligated to apply a
multiple testing procedure to control a selected error measure
[58,63]. However, this would introduce a bias in the obtained
results because both, the selected error measure and the control
procedure, effect the results. In order to minimize this influence (it
is probably not possible to completely eliminate this influence) one
would need to study which pathway-based method works best
 
 
 
Figure 6. Average correlations for individual pathways for ALL (blue) and prostate cancer (violet) are shown by horizontally dashed
lines. The two curves correspond to the rank ordered correlation values for ALL (blue) and prostate cancer (violet). For ST I (green -
r[f0:0,0:2,0:40:6g), ST II (orange - r[f0:2,0:4,0:6g), ST III (purple, r~0:0) and ST IV (brown - r[f0:2,0:4,0:6g) the projections of the range of
correlation values is shown on the right-hand side.
doi:10.1371/journal.pone.0037510.g006
Figure 7. Distribution of the detection call (DC) values for gene
expression data from prostate cancer (left) and ALL (right).
doi:10.1371/journal.pone.0037510.g007
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However, these technical adjustments would not contribute to a
better understanding of the power of a pathway-based method
itself.
The optimal experimental design for microarray experiments
with respect to the identification of the DEP is an important topic
that is currently still under debate. From our comprehensive
analysis of simulated and experimental gene expression data of
over 3 million pathways, we obtain three major results. First, we
find that the heterogeneity of different biological conditions and
the sensitivity of the statistical methods suggest a selective
application to definite pathways. That means, it is not advisable
to apply a method to all accessible pathways but only to selected
ones. Second, future gene expression experiments aiming to detect
the DEP should be conducted with an increased number of
samples in order to avoid non-robust and underpowered studies.
From our study, we find method-specific recommendations
constituting lower bounds for minimal sample sizes. Specifically,
we suggest sample sizes between 60 and 85 to avoid (1) an
underpowered study and (2) to allow the control of the FPR.
Third, as a more theoretical finding we gained insight into the
correlation structure of biological and simulated microarray data.
From these results, we suggest the combined usage of ST III and
ST IV for simulating gene expression data. Because these
simulation types lead to a more realistic correlation structure
compared to studies employing a constant, a random or no
correlation structure at all. On a side note, we would like to
remark that by using simulation methods like GeneNetWeaver [64] or
SynTReN [65], which are aiming to mimic the mechanistic
behavior of the transcription regulation of genes, it is also possible
to obtain simulated expression data with a realistic correlation
structure. However, the generation of data from sampling is
simpler and usually less time consuming. Further, the controlled,
concerted modification of expression levels of genes in particular
pathways may be very challenging for such methods.
For future studies of DEP methods, simulations based on our
approach using ST III and ST IV can be very useful to investigate,
e.g., the influence of different gene network structures, the effect of
overlapping pathways or the influence of heterogeneous effect
sizes. For example, one could compare protein networks and
transcriptional regulatory networks for different organisms or
compare them with gene regulatory networks. Here by gene
regulatory networks we mean networks inferred from gene
expression data [66]. Also different gene regulatory networks
inferred from different inference methods [67–70] could be
studied to investigate distinctions on the pathway level. Regarding
overlapping pathways and their potential importance for pathway
methods, such simulation settings provide ample opportunity to
control parameters for testing hypotheses about their influence.
Lastly, for our study we used a constant effect size for the
differentially expression of genes. That means, we sampled
differentially expressed genes for the control group from N(m,1)
with m~const. This is similar to all previous studies we are aware
of, e.g., [13,25]. However, it could be intricate to identify a
distribution from which the mean m should be sampled.
The studied methods in this paper are expected to be also useful
for the analysis of RNA-seq data [71,72]. For this reason, once a
sufficiently large data set is available, it would be interesting to
repeat the above investigations for this new data type in order to
gain a deeper insight into their experimental design in the context
of DEP. Another important future direction to explore would be
an investigation of the influence that alterations in regulation
mechanisms in pathways have on the biological function [8].
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